Why the study?
Does captopril improve peripheral hemodynamics in patients with severe congestive heart failure, and are prostaglandins involved in this mechanism?
Does captopril improve peripheral hemodynamics in patients with severe congestive heart failure, and are prostaglandins involved in this mechanism?
Captopril improves peripheral hemodynamics in severe heart failure partly through a prostaglandin-dependent mechanism.
Suggests prostaglandin role in captopril's HF effects; hypothesis-generating and should not change practice.
The effects of captopril on the forearm hemodynamics in patients with severe congestive heart failure were studied, using strain-gauge plethysmography. To determine whether prostaglandins are involved in the captopril actions, indomethacin, an inhibitor of prostaglandin synthesis, was administered. In 8 patients, captopril (25 mg) decreased mean blood pressure (P less than 0.01) and venous pressure (P less than 0.05); forearm blood flow (P less than 0.05) and maximum venous volume (P less than 0.05) were increased; forearm vascular resistance (P less than 0.05) and forearm venous tone (P less than 0.05) were decreased. Venous distensibility was improved with captopril (P less than 0.05). All the hemodynamic changes were attenuated by indomethacin (50 mg). Captopril increased circulating bradykinin (P less than 0.05), prostaglandin E2 (P less than 0.05) and 6-keto-prostaglandin F1 alpha (P less than 0.05). Indomethacin did not affect bradykinin level but blocked the increase in prostaglandins. These data suggest that captopril dilates both arterial and venous vessels not only by blocking the renin-angiotensin system but by increasing local or circulating vasodilator prostaglandins.
No takes yet. Share an insight, caveat, or question.
Nishimura et al. (1987) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: